Business

Commercial Launch of AxisBiotix-PsT

Commercial Launch of AxisBiotix-PsT.

articleSkinbiotherapeutics PlcOctober 29, 20215/company/skinbiotherapeutics-plc/news/commercial-launch-of-axisbiotix-pst
Commercial Launch of AxisBiotix-PsT

About this update from Skinbiotherapeutics Plc

[{"type":"text","content":"\n \n \n \n RNS Number : 6358Q\n SkinBioTherapeutics PLC\n 29 October 2021\n  \n \n \n \n 29 October 2021\n \n \n  \n \n \n SkinBioTherapeutics plc\n \n \n (\"SkinBioTherapeutics\" or \"the Company\")\n \n \n  \n \n \n Commercial Launch of AxisBiotix-Ps™ Psoriasis Food Supplement\n \n \n \n · \n \n AxisBiotix-Ps™\n \n successfully launches today on World Psoriasis Day - 29 October 2021\n \n \n · \n Product now on sale online at \n https://axis-biotix.myshopify.com\n \n \n · AxisBiotix-Ps™ now being shipped to the UK and US, with a subscription price per sachet of £1.50 / $2.00\n \n SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, has today announced the commercial launch of AxisBiotix-Ps™, its probiotic food supplement to help alleviate the symptoms associated with psoriasis, on World Psoriasis Day - 29 October 2021. The launch \n follows the highly positive results from its \n \n consumer study \n which concluded in May 2021.\n \n \n  \n \n \n Stuart Ashman, CEO of SkinBioTherapeutics, said:\n \n \n \"The launch of our first commercial product is a momentous occasion for SkinBioTherapeutics. The interest in AxisBiotix-Ps™, and overwhelmingly positive response from participants, has been hugely encouraging. We're delighted to introduce our product to the market on the most important of days for the global psoriasis community, as planned. \n \n \n \"Since the exciting results from the consumer study, announced back in May this year, \n we have seen an growing interest in our product. \n We have been working hard ever since to establish a reliable supply chain to ensure a continuous supply to all our customers upon launch.\n \n \n \"I want to thank the team for their efforts \n to make the launch possible in Q4\n of 2021, on schedule.\"\n \n \n  \n \n \n As previously announced in the \n \n progress update\n \n , commercialisation will start today in the UK and the US markets, with customers able to access the product at \n \n https://axis-biotix.myshopify.com\n \n .\n \n \n  \n \n \n AxisBiotix-Ps\n ™\n will be sold primarily on a subscription basis and is priced per sachet (including VAT and excluding shipping and any duty costs) in the US at $2.00 (USD), in the UK £1.50 (GBP), and in due course in Europe at €1.80 (EUR). \n As demonstrated in the con...

More updates from Skinbiotherapeutics Plc